Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

856
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
856
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

976
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
976
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.

Epilepsia·2026
Same author

Negative motor areas: functional connectivity using stereoelectroencephalography.

NeuroImage·2026
Same author

Isolated hippocampal sclerosis and focal dysplasia type IIIa: Comparative study of anatomo-electro-clinical profile and seizure outcome.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025
Same author

Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO<sub>2</sub>MSE): a prospective, multicentre case-control study.

The Lancet. Neurology·2025
Same author

Cerebral Cavernous Malformations and Focal Drug-Resistant Epilepsy: Behind a Quid Pro Quo of Lesion and Epileptogenic Networks.

European journal of neurology·2025
Same author

Efficacy of naloxone in reducing hypoxemia and duration of immobility following focal to bilateral tonic-clonic seizures.

Epilepsia open·2025

Related Experiment Video

Updated: Jan 27, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

12.9K

Epilepsy treatment in the elderly.

Arnaud Biraben1, Lucie De Clerck2, Anca Nica1

  • 1Service de neurologie, Unité d'épileptologie, CHU de Rennes, Rennes France.

Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|March 28, 2019
PubMed
Summary

As populations age, epilepsy management in elderly patients becomes complex due to comorbidities. Newer anti-epileptic drugs offer better tolerability and fewer interactions, enabling personalized treatment strategies for this demographic.

Keywords:
antiepileptic drugselderlyepilepsynew therapeutic optionspersonalized treatment

More Related Videos

Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring
11:28

Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring

Published on: June 13, 2025

1.3K
Evaluating the Function of the Foot Core System in the Elderly
08:25

Evaluating the Function of the Foot Core System in the Elderly

Published on: March 11, 2022

3.2K

Related Experiment Videos

Last Updated: Jan 27, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

12.9K
Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring
11:28

Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring

Published on: June 13, 2025

1.3K
Evaluating the Function of the Foot Core System in the Elderly
08:25

Evaluating the Function of the Foot Core System in the Elderly

Published on: March 11, 2022

3.2K

Area of Science:

  • Geriatrics
  • Neurology
  • Clinical Pharmacology

Background:

  • Global population aging increases the incidence of epilepsy in older adults.
  • Elderly patients present unique diagnostic and treatment challenges for epilepsy.
  • Physiological aging, comorbidities, and polypharmacy complicate epilepsy management.

Purpose of the Study:

  • To review the challenges in managing epilepsy in the aging population.
  • To evaluate the role of newer anti-epileptic drugs in this demographic.
  • To discuss personalized treatment approaches for elderly epilepsy patients.

Main Methods:

  • Literature review of epilepsy in aging populations.
  • Analysis of pharmacokinetic and pharmacodynamic changes with age.
  • Comparison of older versus newer anti-epileptic drug profiles.

Main Results:

  • Newer anti-epileptic drugs demonstrate improved tolerability and patient compliance.
  • Novel anti-epileptic drugs often require less frequent dosing and reduced monitoring.
  • Newer agents exhibit fewer drug-drug interactions compared to older formulations.

Conclusions:

  • Despite increased complexity, advances in anti-epileptic drugs allow for personalized epilepsy treatment in the elderly.
  • Careful selection of anti-epileptic drugs is crucial for managing comorbidities and polypharmacy.
  • Optimized pharmacotherapy can improve quality of life for aging individuals with epilepsy.